

SAFETY DATA SHEETS

This SDS packet was issued with item:

078465894

N/A



MATERIAL SAFETY DATA SHEET

Revision date: 06-Apr-2010

Version: 1.2

Page 1 of 6

1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-212-573-2222

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161
Emergency telephone number:
ChemSafe (24 hours): +44 (0)208 762 8322

Material Name: Medroxyprogesterone Acetate Injectable Suspension, 400 mg/ml

Trade Name:	DEPO-PROVERA® Sterile Aqueous Suspension
Chemical Family:	Mixture
Intended Use:	Pharmaceutical product used for menstrual irregularities

2. HAZARDS IDENTIFICATION

Appearance: Clear liquid
Signal Word: DANGER

Statement of Hazard: May cause cancer.
May damage fertility or the unborn child.

Additional Hazard Information:

Short Term:	Not an eye irritant ; Not a skin irritant ; Not acutely toxic (based on animal data) .
Long Term:	Repeat-dose studies in animals have shown a potential to cause adverse effects on blood and blood forming organs, reproductive system, the developing fetus. Occupational studies have shown that males working with estrogen-like compounds have shown clinical signs of hyperestrogenism including enlarged breasts and milk secretion. Loss of libido, breast tenderness, and changes in sex hormone levels have also occurred. Occupational exposure in females has resulted in menstrual irregularities (breakthrough bleeding, menstrual flow changes, spotting and amenorrhea).

Known Clinical Effects: Adverse effects associated with therapeutic use of medroxyprogesterone acetate include menstrual irregularities, abdominal pain or discomfort weight changes, dizziness, headache, weakness or fatigue, and nervousness. Clinical use of this drug has caused loss of libido impotence development of male characteristics in the female fetus

EU Classification

EU Indication of danger: Toxic to reproduction: Category 1
Carcinogenic: Category 2

EU Hazard Symbols:



EU Risk Phrases:

R45 - May cause cancer.
R60 - May impair fertility.
R61 - May cause harm to the unborn child.

MATERIAL SAFETY DATA SHEET

Material Name: Medroxyprogesterone Acetate Injectable
Suspension, 400 mg/ml
Revision date: 06-Apr-2010

Page 2 of 6

Version: 1.2

2. HAZARDS IDENTIFICATION

Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	%
Medroxyprogesterone acetate	71-58-9	200-757-9	Carc. Cat.2;R45 Repr. Cat.1;R60-61	40

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	%
Non-hazardous Ingredients	Proprietary	Not listed	Not Listed	*
Water	7732-18-5	231-791-2	Not Listed	*

Additional Information: * Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

For the full text of the R phrases mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Eye Contact: Immediately flush eyes with water for at least 15 minutes. If irritation occurs or persists, get medical attention.

Skin Contact: Wash off immediately with soap and plenty of water. If irritation occurs or persists, get medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products: Carbon dioxide, carbon monoxide

Fire Fighting Procedures: During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

Fire / Explosion Hazards: Not applicable

MATERIAL SAFETY DATA SHEET

Material Name: Medroxyprogesterone Acetate Injectable
Suspension, 400 mg/ml
Revision date: 06-Apr-2010

Page 3 of 6

Version: 1.2

6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions:	Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.
Measures for Cleaning / Collecting:	Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.
Measures for Environmental Protections:	Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.
Additional Consideration for Large Spills:	Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

General Handling:	Avoid contact with eyes, skin and clothing. Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.
Storage Conditions:	Store as directed by product packaging.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Medroxyprogesterone acetate

Pfizer OEL TWA-8 Hr:

2 µg/m³, Skin

The exposure limit(s) listed for solid components are only relevant if dust or mist may be generated.

Analytical Method:	Analytical method available for Medroxyprogesterone. Contact Pfizer Inc for further information.
Engineering Controls:	Engineering controls should be used as the primary means to control exposures.
Environmental Exposure Controls:	Refer to specific Member State legislation for requirements under Community environmental legislation.
Personal Protective Equipment:	Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).
Hands:	Rubber gloves
Eyes:	Not required under normal conditions of use. Wear safety glasses or goggles if eye contact is possible.
Skin:	Not required for the normal use of this product. Wear protective clothing when working with large quantities.
Respiratory protection:	Not required for the normal use of this product. If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Liquid	Color:	Clear
Molecular Formula:	Mixture	Molecular Weight:	Mixture
Solubility:	Soluble: Water		

MATERIAL SAFETY DATA SHEET

Material Name: Medroxyprogesterone Acetate Injectable
Suspension, 400 mg/ml
Revision date: 06-Apr-2010

Page 4 of 6

Version: 1.2

9. PHYSICAL AND CHEMICAL PROPERTIES

10. STABILITY AND REACTIVITY

Chemical Stability: Stable under normal conditions of use.
Conditions to Avoid: None
Incompatible Materials: None

11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of the active ingredient(s).

Acute Toxicity: (Species, Route, End Point, Dose)

Medroxyprogesterone acetate

Rat Oral LD50 > 6,400 mg/kg
Mouse Para-periosteal LD50 376 mg/kg
Rat Intraperitoneal LD50 > 400 mg/kg
Rat Subcutaneous LD50 > 8000 mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Medroxyprogesterone acetate

Eye Irritation Rabbit Non-irritating
Skin Irritation Rabbit Mild

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Medroxyprogesterone acetate

10 Year(s) Monkey Intramuscular 3 mg/kg LOAEL Reproductive system
18 Month(s) Mouse Intramuscular 200 mg/kg NOAEL None identified
24 Month(s) Rat Intramuscular 200 mg/kg NOAEL None identified

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Medroxyprogesterone acetate

Embryo / Fetal Development Rat Intramuscular 3 mg/kg LOAEL Embryotoxicity, Not teratogenic
Embryo / Fetal Development Monkey Intramuscular 25 mg/kg LOAEL Developmental toxicity
Embryo / Fetal Development Rabbit Intramuscular 1 mg/kg LOAEL Developmental toxicity
Embryo / Fetal Development Rat Subcutaneous 1 mg/kg LOAEL Developmental toxicity

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Medroxyprogesterone acetate

Bacterial Mutagenicity (Ames) *Salmonella* Negative
Micronucleus Mouse Negative
Chromosome Aberration Rodent germ cell Positive
Sister Chromatid Exchange Rodent Lymphocytes Positive

MATERIAL SAFETY DATA SHEET

Material Name: Medroxyprogesterone Acetate Injectable
Suspension, 400 mg/ml
Revision date: 06-Apr-2010

Page 5 of 6

Version: 1.2

11. TOXICOLOGICAL INFORMATION

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Medroxyprogesterone acetate

18 Month(s)	Mouse	Intramuscular	200 mg/kg/month	Not carcinogenic
24 Month(s)	Rat	Intramuscular	200 mg/kg/month	Not carcinogenic
18 Month(s)	Dog	Intramuscular	0.2 mg/kg	LOEL Benign tumors
40 Month(s)	Dog	Intramuscular	0.3 mg/kg	NOAEL Tumors, Mammary gland

Carcinogen Status: See below

Medroxyprogesterone acetate
IARC:

Group 2B

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been investigated. Releases to the environment should be avoided.

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

EU Symbol: T
EU Indication of danger: Toxic to reproduction: Category 1
Carcinogenic: Category 2

EU Risk Phrases:
R45 - May cause cancer.
R60 - May impair fertility.
R61 - May cause harm to the unborn child.

EU Safety Phrases:
S36/37 - Wear suitable protective clothing and gloves.
S53 - Avoid exposure - obtain special instructions before use.

MATERIAL SAFETY DATA SHEET

Material Name: Medroxyprogesterone Acetate Injectable
Suspension, 400 mg/ml
Revision date: 06-Apr-2010

Page 6 of 6

Version: 1.2

15. REGULATORY INFORMATION

OSHA Label:

DANGER

May cause cancer.

May damage fertility or the unborn child.

Canada - WHMIS: Classifications

WHMIS hazard class:

Class D, Division 2, Subdivision A



Medroxyprogesterone acetate

California Proposition 65

carcinogen, initial date 1/1/90

developmental toxicity, initial date 4/1/90

Inventory - United States TSCA - Sect. 8(b)

Listed

Australia (AICS):

Listed

EU EINECS/ELINCS List

200-757-9

Water

Inventory - United States TSCA - Sect. 8(b)

Listed

Australia (AICS):

Listed

REACH - Annex IV - Exemptions from the obligations of Register:

Present

EU EINECS/ELINCS List

231-791-2

16. OTHER INFORMATION

Text of R phrases mentioned in Section 3

R45 - May cause cancer.

R60 - May impair fertility.

R61 - May cause harm to the unborn child.

Data Sources:

Pfizer proprietary drug development information.

Reasons for Revision:

Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking.
Updated Section 3 - Composition / Information on Ingredients.

Prepared by:

Toxicology and Hazard Communication
Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet



SAFETY DATA SHEET

Revision date: 11-Aug-2014

Version: 6.0

Page 1 of 10

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Medroxyprogesterone Acetate Injectable Suspension, USP, 150 mg/ml

Trade Name: DEPO-PROVERA; DEPO-PRODASONE; FARLUTAL; FARLUTAL DEPO; ONCO-PROVERA; DEPO-RALOVERA; SAYANA; DEPOCON

Synonyms: Medroxyprogesterone Suspension, For Injection, IM

Chemical Family: Mixture

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product used as contraceptive agent

Details of the Supplier of the Safety Data Sheet

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-800-879-3477

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

Emergency telephone number:
International CHEMTREC (24 hours): +1-703-527-3887

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification

Reproductive Toxicity: Category 1A

Carcinogenicity: Category 2

EU Classification:

EU Indication of danger: Toxic to reproduction: Category 1

Carcinogenic: Category 2

EU Risk Phrases:

R45 - May cause cancer.

R60 - May impair fertility.

R61 - May cause harm to the unborn child.

Label Elements

Signal Word: Danger

Hazard Statements: H351 - Suspected of causing cancer
H360FD - May damage fertility. May damage the unborn child.

SAFETY DATA SHEET

Material Name: Medroxyprogesterone Acetate Injectable
Suspension, USP, 150 mg/ml
Revision date: 11-Aug-2014

Page 2 of 10

Version: 6.0

Precautionary Statements:

- P201 - Obtain special instructions before use
- P202 - Do not handle until all safety precautions have been read and understood
- P308 + P313 - IF exposed or concerned: Get medical attention/advice
- P405 - Store locked up
- P501 - Dispose of contents/container in accordance with all local and national regulations



Other Hazards
Australian Hazard Classification (NOHSC):

No data available
Hazardous Substance. Non-Dangerous Goods.

Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Medroxyprogesterone acetate	71-58-9	200-757-9	Carc. Cat.3;R40 Repr. Cat.1;R60-61	Carc. 2 (H351) Repr. 1A (H360FD)	15
Sodium chloride	7647-14-5	231-598-3	Not Listed	Not Listed	*
Polyethylene glycol	25322-68-3	Not Listed	Not Listed	Not Listed	*

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Methylparaben	99-76-3	202-785-7	Not Listed	Not Listed	*
Water for injection	7732-18-5	231-791-2	Not Listed	Not Listed	*
Polysorbate 80	9005-65-6	Not Listed	Not Listed	Not Listed	*
Propylparaben	94-13-3	202-307-7	Not Listed	Not Listed	*

Additional Information:

- * Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the R phrases and CLP/GHS abbreviations mentioned in this Section, see Section 16

SAFETY DATA SHEET

Material Name: Medroxyprogesterone Acetate Injectable
Suspension, USP, 150 mg/ml
Revision date: 11-Aug-2014

Page 3 of 10

Version: 6.0

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact:	Flush eyes with water for at least 15 minutes. If irritation occurs or persists, get medical attention.
Skin Contact:	Remove contaminated clothing. Flush area with large amounts of water. If irritation occurs or persists, get medical attention.
Ingestion:	Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.
Inhalation:	Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure:	For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.
Medical Conditions Aggravated by Exposure:	None known

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician:	None
----------------------------	------

5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO2, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products:	Carbon dioxide, carbon monoxide
Fire / Explosion Hazards:	Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting:	Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.
Additional Consideration for Large Spills:	Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

SAFETY DATA SHEET

Material Name: Medroxyprogesterone Acetate Injectable
Suspension, USP, 150 mg/ml
Revision date: 11-Aug-2014

Page 4 of 10

Version: 6.0

7. HANDLING AND STORAGE

Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.
Specific end use(s): Pharmaceutical drug product

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

Medroxyprogesterone acetate

Pfizer OEL TWA-8 Hr: 2 µg/m³, Skin

Sodium chloride

Latvia OEL - TWA 5 mg/m³

Lithuania OEL - TWA 5 mg/m³

Polyethylene glycol

Austria OEL - MAKs 1000 mg/m³

Germany - TRGS 900 - TWAs 1000 mg/m³

Germany (DFG) - MAK 1000 mg/m³ average molecular weight 200-600

Slovakia OEL - TWA 1000 mg/m³

Slovenia OEL - TWA 1000 mg/m³

Switzerland OEL - TWAs 1000 ppm

Exposure Controls

Engineering Controls: Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Personal Protective Equipment: Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

Hands: Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.

Eyes: Wear safety glasses or goggles if eye contact is possible.

Skin: Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.

Respiratory protection: If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Liquid suspension
Odor: No data available.
Molecular Formula: Mixture

Color: White to off-white
Odor Threshold: No data available.
Molecular Weight: Mixture

Solvent Solubility: No data available
Water Solubility: No data available

SAFETY DATA SHEET

Material Name: Medroxyprogesterone Acetate Injectable
Suspension, USP, 150 mg/ml
Revision date: 11-Aug-2014

Page 5 of 10

Version: 6.0

9. PHYSICAL AND CHEMICAL PROPERTIES

Solubility: Soluble: Water
pH: No data available.
Melting/Freezing Point (°C): No data available
Boiling Point (°C): No data available.
Partition Coefficient: (Method, pH, Endpoint, Value)
Medroxyprogesterone acetate
No data available
Water for injection
No data available
Polysorbate 80
No data available
Propylparaben
No data available
Methylparaben
No data available
Sodium chloride
No data available
Polyethylene glycol
No data available
Decomposition Temperature (°C): No data available.

Evaporation Rate (Gram/s): No data available
Vapor Pressure (kPa): No data available
Vapor Density (g/ml): No data available
Relative Density: No data available
Viscosity: No data available

Flammability:

Autoignition Temperature (Solid) (°C):	No data available
Flammability (Solids):	No data available
Flash Point (Liquid) (°C):	No data available
Upper Explosive Limits (Liquid) (% by Vol.):	No data available
Lower Explosive Limits (Liquid) (% by Vol.):	No data available

10. STABILITY AND REACTIVITY

Reactivity: No data available
Chemical Stability: Stable under normal conditions of use.
Possibility of Hazardous Reactions
Oxidizing Properties: No data available
Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.
Incompatible Materials: As a precautionary measure, keep away from strong oxidizers
Hazardous Decomposition Products: No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information: The information included in this section describes the potential hazards of the individual ingredients.

Short Term: Not an eye irritant ; Not a skin irritant ; Not acutely toxic (based on animal data) .

SAFETY DATA SHEET

Material Name: Medroxyprogesterone Acetate Injectable
Suspension, USP, 150 mg/ml
Revision date: 11-Aug-2014

Page 6 of 10

Version: 6.0

11. TOXICOLOGICAL INFORMATION

Long Term: Repeat-dose studies in animals have shown a potential to cause adverse effects on blood and blood forming organs, reproductive system, the developing fetus. Occupational studies have shown that males working with estrogen-like compounds have shown clinical signs of hyperestrogenism including enlarged breasts and milk secretion. Loss of libido, breast tenderness, and changes in sex hormone levels have also occurred. Occupational exposure in females has resulted in menstrual irregularities (breakthrough bleeding, menstrual flow changes, spotting and amenorrhea).

Known Clinical Effects: Adverse effects associated with therapeutic use of medroxyprogesterone acetate include menstrual irregularities, abdominal pain or discomfort weight changes, dizziness, headache, weakness or fatigue, and nervousness. Clinical use of this drug has caused loss of libido impotence development of male characteristics in the female fetus

Acute Toxicity: (Species, Route, End Point, Dose)

Medroxyprogesterone acetate

Rat Oral LD50 > 6,400 mg/kg
Mouse Para-periosteal LD50 376mg/kg
Rat Intraperitoneal LD50 > 400mg/kg
Rat Subcutaneous LD50 > 8000mg/kg

Polysorbate 80

Rat Oral LD50 25 g/kg

Propylparaben

Mouse Oral LD 50 6332 mg/kg
Mouse Sub-tenon injection (eye) LD 50 200 mg/kg

Sodium chloride

Rat Oral LD50 3000 mg/kg
Mouse Oral LD50 4000 mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Medroxyprogesterone acetate

Eye Irritation Rabbit Non-irritating
Skin Irritation Rabbit Mild

Sodium chloride

Eye Irritation Rabbit Moderate
Skin Irritation Rabbit Mild

Polyethylene glycol

Eye Irritation Rabbit Mild
Skin Irritation Rabbit Mild

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Medroxyprogesterone acetate

10 Year(s) Monkey Intramuscular 3 mg/kg LOAEL Reproductive system

SAFETY DATA SHEET

Material Name: Medroxyprogesterone Acetate Injectable
Suspension, USP, 150 mg/ml
Revision date: 11-Aug-2014

Page 7 of 10

Version: 6.0

11. TOXICOLOGICAL INFORMATION

18 Month(s)	Mouse	Intramuscular	200 mg/kg	NOAEL	None identified
24 Month(s)	Rat	Intramuscular	200 mg/kg	NOAEL	None identified

Propylparaben

3 Week(s)	Rat	Oral	27.1 g/kg	LOAEL	Endocrine system
4 Week(s)	Rat	Oral	347.2 mg/kg	LOAEL	Male reproductive system

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Medroxyprogesterone acetate

Embryo / Fetal Development	Rat	Intramuscular	3 mg/kg	LOAEL	Embryotoxicity, Not teratogenic
Embryo / Fetal Development	Monkey	Intramuscular	25 mg/kg	LOAEL	Developmental toxicity
Embryo / Fetal Development	Rabbit	Intramuscular	1 mg/kg	LOAEL	Developmental toxicity
Embryo / Fetal Development	Rat	Subcutaneous	1 mg/kg	LOAEL	Developmental toxicity

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Medroxyprogesterone acetate

Bacterial Mutagenicity (Ames)	<i>Salmonella</i>	Negative
Micronucleus	Mouse	Negative
Chromosome Aberration	Rodent germ cell	Positive
Sister Chromatid Exchange	Rodent Lymphocytes	Positive

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Medroxyprogesterone acetate

18 Month(s)	Mouse	Intramuscular	200 mg/kg/month	Not carcinogenic
24 Month(s)	Rat	Intramuscular	200 mg/kg/month	Not carcinogenic
18 Month(s)	Dog	Intramuscular	0.2 mg/kg	LOEL Benign tumors
40 Month(s)	Dog	Intramuscular	0.3 mg/kg	NOAEL Tumors, Mammary gland

Carcinogen Status: See below

Medroxyprogesterone acetate

IARC:	Group 2B (Possibly Carcinogenic to Humans)
OSHA:	Listed

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been investigated. Releases to the environment should be avoided.

Toxicity: No data available

Persistence and Degradability: No data available

Bio-accumulative Potential: No data available

Mobility in Soil: No data available

SAFETY DATA SHEET

Material Name: Medroxyprogesterone Acetate Injectable
Suspension, USP, 150 mg/ml
Revision date: 11-Aug-2014

Page 8 of 10

Version: 6.0

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods:

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Canada - WHMIS: Classifications

WHMIS hazard class:

Class D, Division 2, Subdivision A



Medroxyprogesterone acetate

CERCLA/SARA 313 Emission reporting
California Proposition 65

Inventory - United States TSCA - Sect. 8(b)
Australia (AICS):
EU EINECS/ELINCS List

Not Listed
carcinogen initial date 1/1/90
developmental toxicity initial date 4/1/90
Present
Present
200-757-9

Methylparaben

CERCLA/SARA 313 Emission reporting
California Proposition 65

Inventory - United States TSCA - Sect. 8(b)
Australia (AICS):
EU EINECS/ELINCS List

Not Listed
Not Listed
Present
Present
202-785-7

SAFETY DATA SHEET

Material Name: Medroxyprogesterone Acetate Injectable
Suspension, USP, 150 mg/ml
Revision date: 11-Aug-2014

Page 9 of 10

Version: 6.0

15. REGULATORY INFORMATION

Water for injection

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	231-791-2

Polysorbate 80

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed

Sodium chloride

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	231-598-3

Polyethylene glycol

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 3
EU EINECS/ELINCS List	Not Listed

Propylparaben

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	202-307-7

16. OTHER INFORMATION

Text of R phrases and GHS Classification abbreviations mentioned in Section 3

Reproductive toxicity-Cat.1A; H360FD - May damage fertility. May damage the unborn child.
Carcinogenicity-Cat.2; H351 - Suspected of causing cancer

Carcinogenic: Category 3
Toxic to reproduction: Category 1

SAFETY DATA SHEET

Material Name: Medroxyprogesterone Acetate Injectable
Suspension, USP, 150 mg/ml
Revision date: 11-Aug-2014

Page 10 of 10

Version: 6.0

R45 - May cause cancer.

R60 - May impair fertility.

R61 - May cause harm to the unborn child.

Data Sources: Pfizer proprietary drug development information. Publicly available toxicity information. Safety data sheets for individual ingredients.

Reasons for Revision: Updated Section 2 - Hazard Identification. Updated Section 15 - Regulatory Information. Updated Section 3 - Composition / Information on Ingredients. Updated Section 7 - Handling and Storage. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 16 - Other Information.

Revision date: 11-Aug-2014

Product Stewardship Hazard Communication

Prepared by: Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet